Investigating the effect of age on AAV2 and AAV8 delivery and transgene expression via subretinal injection in mice

ASGCT 2025 -- Inherited retinal diseases (IRDs) and age-related macular degeneration (AMD) affect patients of all ages with current therapies intended to slow but not cure disease. Gene therapy shows great potential to both treat and cure retinal disorders. Due to the wide range in patient ages, it is important to understand how age affects the delivery and expression of therapeutic transgenes via rAAV vectors. Both AAV2 and AAV8 serotypes are commonly utilized in ocular gene therapy. We investigated the effect of age AAV2 and AAV8 vector serotypes with the goal of evaluating vector delivery/transgene expression and tolerability.